Clinical outcomes, virological efficacy and safety of nitazoxanide in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

The African Kelleni’s roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one

“…Moreover, Vaz et al ( 2023 ) have also only referenced two clinical trials previously discussed in this manuscript (Blum et al 2021 ; Patricia et al 2021 ), and yet, they doubted nitazoxanide effectiveness against COVID-19 and we would like to suggest that their judgment would be corrected when they consider other trials that were not cited or discussed and that their even their two cited references imply potential benefit that should have urged them to at least adopt a more cautious scientific impression. Similarly, though Weng et al’s analysis has shown the superiority of nitazoxanide over placebo and standard of care regarding SARS CoV-2 eradication rate and acknowledged its excellent safety, they have unfortunately ignored the limitations of their study and recommended against its use in COVID-19 (Weng et al 2022 ). Regrettably, even the authors who honestly admit some major limitations in their studies should have never concluded lack of evidence that supports the use of nitazoxanide to manage COVID-19, while even their cited references argue their conclusion (Martins-Filho et al 2022 ), not to mention that other meta-analysis studies have shown proved clinical benefit as decreasing oxygen requirements and called for large-scale studies to elucidate other disputed benefits (Abuelazm et al 2022 ).…”